Introduction: Fms-related tyrosine kinase 3 (FLT3) mutation, which is considered a poor prognostic marker, is identified in 25%-45% of patients with acute myeloid leukemia (AML), and nucleophosmin (NPM1) mutation, which predicts a favorable outcome in the absence of FLT3 mutation, has been identified in approximately 35% of patients with AML. The relevance of these mutations to induction chemotherapy (IC) outcomes in AfricanAmerican patients has not been studied. Materials and Methods: Twenty consecutive cases of AML were identified and their records reviewed for clinical and laboratory data, treatment, and its outcomes. Data for karyotypic analysis, fluorescent in situ hybridization studies, and mutational analysis for FLT3 and NPM1 (performed on bone marrow) were collected.
Results: FLT3 mutation was present in six of 20 AML patients, and NPM1 mutation was present in four of 20 AML patients. Thirteen of the twenty patients did not achieve remission after induction chemotherapy. The four (4/6) patients with sole FLT3 mutation were unresponsive to IC irrespective of favorable karyotype t(8;21) in a patient, and the other two (2/6) patients with additional NPM1 mutation showed complete response to IC. Of the 14 patients negative for FLT3 mutation, the two positive for NPM1 mutation showed complete response to IC in spite of complex karyotypes. Of the patients (12) negative for both FLT3 and NPM1 mutations, three patients showed complete response to IC. Conclusion: In general, African-American patients had poor response to IC. All patients with NPM1 mutation had complete response to IC. Patients with FLT3 mutation but without NPM1 mutation were all unresponsive to IC, while those with both FLT3 and NPM1 mutations had complete response to IC and have remained in remission. Contrary to prevailing concept, we found NPM1 mutation to be associated with favorable outcome to IC even in patients with positive FLT3.
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Background: Programmed cell death ligand 1 (PD-L1) is a cell surface glycoprotein that down-regulates the immune responses through binding to its inhibitory receptor (PD-1) on T cells. Primary effusion lymphoma (PEL) is an uncommon, large B-cell non-Hodgkin lymphoma associated with immunosuppression. Given the lack of literature on PD-L1 expression in PEL and potential targetable immunotherapy, we evaluated PD-L1 expression in PEL with clinical correlation. Design: Seven cases of PEL with both tissue and clinical data were available for review. IHC was performed using monoclonal antibodies against PD-L1 (SP142) and PD1 (NAT105). PD-L1 immunoreactivity was scored in the neoplastic cells (nPD-L1) as percentage (%) of neoplastic cells and was stratified into low (< 5%) and high expression (≥5%) groups. We also scored PD-L1 expression in the stromal cells (sPD-L1) as the percentage of cells staining in tumor region. PD-1 was scored as the number of positive T-cells per high power field (HPF). Results: All subjects were men. The median age was 64 years. Specimen types included five pleural or pericardial fluids, and two extracavitary lymph nodes. A higher expression of nPD-L1 was observed only in two cases,
